Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date Issued: July 13, 2026
Subject: Announcement of positive interim results from the registrational Phase II AZUR-1 trial for Jemperli (dostarlimab) in patients with stage II/III dMMR/MSI-H locally advanced rectal cancer.
Key Financial Metrics
This filing is a clinical development update and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
- Primary Objective Met: The AZUR-1 trial met its primary endpoint, demonstrating a meaningful and sustained clinical complete response rate at 12 months (cCR12).
- Treatment Potential: Results suggest dostarlimab may eliminate or delay the need for chemotherapy, radiation, and surgery in some patients with dMMR/MSI-H locally advanced rectal cancer.
- Study Design: A global, open-label, single-arm trial involving 154 participants who received nine cycles of dostarlimab (500 mg IV every three weeks) over six months.
- Safety Profile: Interim data indicates the safety and tolerability profile is consistent with the drug's well-characterized profile in solid tumors.
Outlook, Regulatory Status, and Risks
- Regulatory Path: GSK plans to share interim data with global health authorities to support regulatory review, including an accelerated review in the US.
- Designations: Dostarlimab holds Breakthrough Therapy and Fast Track designations from the FDA for this indication.
- Current Approval Status: Jemperli is not currently approved anywhere in the world for rectal cancer.
- Forward-Looking Risks: The filing includes a cautionary statement that actual results may differ materially from projections due to risks described in GSK's 2025 Form 20-F and Q1 2026 results.
Key Facts for Investor Verification
- Verify the specific numerical value of the clinical complete response rate (cCR12) in the full data presentation or subsequent regulatory filings, as the text only describes it as "meaningful."
- Confirm the timeline for the submission of data to the FDA and other global regulatory authorities.
- Monitor the upcoming scientific congress where detailed results will be presented.
- Review the "Risk Factors" section of the 2025 Annual Report on Form 20-F for specific uncertainties regarding drug development and regulatory approval.